Channel Therapeutics Corporation
Research Channel Therapeutics Corporation (PTHS) on Bullrun: market cap USD 72.59M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTHS
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 72.59M
- Financial periodQ2 2026
- RevenueUSD 15.60M
- Net income-USD 23.42M
- Free cash flow-USD 7.67M
- Gross margin17.8%
Valuation Snapshot
latest market cap is USD 72.59M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 16.80M | -USD 43.32M | -USD 22.69M | 76.3% | -23.04 | USD 17.97M | USD 34.83M | USD 38.88M |
| FY2024 | USD 0 | -USD 7.96M | -USD 5.79M | n/a | -14.27 | USD 513.00K | USD 2.19M | -USD 2.71M |
| FY2023 | USD 0 | -USD 7.38M | -USD 981.03K | n/a | -5.78 | USD 100.00K | USD 1.27M | -USD 6.45M |
| FY2022 | USD 0 | -USD 2.46M | -USD 1.57M | n/a | -2.65 | USD 100.00K | USD 540.43K | -USD 3.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 72.59M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.45M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.91M | n/a | n/a | n/a |
About Channel Therapeutics Corporation
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Channel Therapeutics Corporation's market cap?
Channel Therapeutics Corporation's market capitalization is USD 72.59M.
What does Channel Therapeutics Corporation do?
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.